Cargando…
Do we need nasal vaccines against COVID 19 to suppress the transmission of infections?
Covid‐19 vaccines have within the first year prevented about 14 million deaths but did not induce a strong mucosal immune response. Data from US, UK, Singapore and Israel showed a variable and mostly modest effects of vaccination on virus excretion during breakthrough infections. Contact studies sho...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9803331/ https://www.ncbi.nlm.nih.gov/pubmed/36464938 http://dx.doi.org/10.1111/1751-7915.14181 |
_version_ | 1784861861813944320 |
---|---|
author | Brüssow, Harald |
author_facet | Brüssow, Harald |
author_sort | Brüssow, Harald |
collection | PubMed |
description | Covid‐19 vaccines have within the first year prevented about 14 million deaths but did not induce a strong mucosal immune response. Data from US, UK, Singapore and Israel showed a variable and mostly modest effects of vaccination on virus excretion during breakthrough infections. Contact studies showed decreased transmission of infection from vaccinated index cases, but the effect varied according to dominant virus type, with study type and the nature of the contact group and diminished with time after vaccination. Some researchers suspect that it is unlikely to stop the pandemic with injected vaccines alone. Promising animal experiments were conducted with mucosal vaccines. Mice nasally immunized with a chimpanzee adenovirus vector mounted a mucosal immune response, were protected against viral challenge after a single vaccine dose and suppressed nasal replication of the challenge virus. Phage T4 expressing SARS‐CoV‐2 spike and nucleocapsid induced a sterilizing lung immunity in nasally vaccinated mice. Also hamsters intranasally immunized with the prefusion‐stabilized spike protein showed no infectious virus in nasal turbinates upon challenge. Other studies showed that intranasal vaccination with an adenovirus vaccine reduced but did not eliminated viral transmission from infected to naïve hamsters. Intranasal vaccination of rhesus macaques with adenovirus vaccines also substantially reduced or even suppressed viral replication in the upper and lower respiratory tract. Human data on mucosal SARS‐CoV‐2 vaccines are so far limited to safety and immunogenicity studies. Aerosolized adenovirus vaccines given either as a booster or as primary immunization were safe and induced similar or superior immune response than injected vaccines while an aerosolized influenza vectored vaccine induced only a weak humoral and cellular immune response. Overall 100 mucosal SARS‐CoV‐2 vaccines are in development and 20 are in clinical trials. First human trials demonstrate that this will not be an easy task. |
format | Online Article Text |
id | pubmed-9803331 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-98033312023-01-04 Do we need nasal vaccines against COVID 19 to suppress the transmission of infections? Brüssow, Harald Microb Biotechnol Lilliput Covid‐19 vaccines have within the first year prevented about 14 million deaths but did not induce a strong mucosal immune response. Data from US, UK, Singapore and Israel showed a variable and mostly modest effects of vaccination on virus excretion during breakthrough infections. Contact studies showed decreased transmission of infection from vaccinated index cases, but the effect varied according to dominant virus type, with study type and the nature of the contact group and diminished with time after vaccination. Some researchers suspect that it is unlikely to stop the pandemic with injected vaccines alone. Promising animal experiments were conducted with mucosal vaccines. Mice nasally immunized with a chimpanzee adenovirus vector mounted a mucosal immune response, were protected against viral challenge after a single vaccine dose and suppressed nasal replication of the challenge virus. Phage T4 expressing SARS‐CoV‐2 spike and nucleocapsid induced a sterilizing lung immunity in nasally vaccinated mice. Also hamsters intranasally immunized with the prefusion‐stabilized spike protein showed no infectious virus in nasal turbinates upon challenge. Other studies showed that intranasal vaccination with an adenovirus vaccine reduced but did not eliminated viral transmission from infected to naïve hamsters. Intranasal vaccination of rhesus macaques with adenovirus vaccines also substantially reduced or even suppressed viral replication in the upper and lower respiratory tract. Human data on mucosal SARS‐CoV‐2 vaccines are so far limited to safety and immunogenicity studies. Aerosolized adenovirus vaccines given either as a booster or as primary immunization were safe and induced similar or superior immune response than injected vaccines while an aerosolized influenza vectored vaccine induced only a weak humoral and cellular immune response. Overall 100 mucosal SARS‐CoV‐2 vaccines are in development and 20 are in clinical trials. First human trials demonstrate that this will not be an easy task. John Wiley and Sons Inc. 2022-12-04 /pmc/articles/PMC9803331/ /pubmed/36464938 http://dx.doi.org/10.1111/1751-7915.14181 Text en © 2022 The Author. Microbial Biotechnology published by Applied Microbiology International and John Wiley & Sons Ltd. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Lilliput Brüssow, Harald Do we need nasal vaccines against COVID 19 to suppress the transmission of infections? |
title | Do we need nasal vaccines against COVID 19 to suppress the transmission of infections? |
title_full | Do we need nasal vaccines against COVID 19 to suppress the transmission of infections? |
title_fullStr | Do we need nasal vaccines against COVID 19 to suppress the transmission of infections? |
title_full_unstemmed | Do we need nasal vaccines against COVID 19 to suppress the transmission of infections? |
title_short | Do we need nasal vaccines against COVID 19 to suppress the transmission of infections? |
title_sort | do we need nasal vaccines against covid 19 to suppress the transmission of infections? |
topic | Lilliput |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9803331/ https://www.ncbi.nlm.nih.gov/pubmed/36464938 http://dx.doi.org/10.1111/1751-7915.14181 |
work_keys_str_mv | AT brussowharald doweneednasalvaccinesagainstcovid19tosuppressthetransmissionofinfections |